ArticleJournal of orthopaedic translation2026
Extracellular vesicles originating from induced pluripotent stem cell-derived chondrocytes facilitate the regeneration of osteoarthritic cartilage.
Article in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Articular cartilage, a highly specialized avascular connective tissue, forms a smooth, load-bearing surface on articulating bone ends to facilitate frictionless joint movement. While cell-derived small extracellular vesicles (sEVs) have emerged as promising therapeutic biomaterials for cartilage regeneration, two major limitations impede their clinical translation: the scarcity of autologous donor cells, and suboptimal functional efficacy of conventional sEVs preparations. Methods: We established an induced pluripotent stem cell (iPSC)-based approach by differentiating iPSCs into chondrocytes (designated iChondrocytes). After characterizing the derived iChondrocytes, we isolated their secreted sEVs (iChondrocyte-sEVs) and systematically evaluated their therapeutic effects and underlying mechanisms in cartilage regeneration through Results: Functional assays revealed that iChondrocyte-sEVs significantly enhanced chondrogenic differentiation, stimulated extracellular matrix (ECM) deposition, and maintained chondrocyte homeostasis. In murine osteoarthritis (OA) models, intra-articularly administered iChondrocyte-sEVs efficiently penetrated deep cartilage layers, alleviated OA-associated pathological changes, and restored cartilage microstructure and biomechanical properties to near-normal levels. Furthermore, therapeutic intervention with iChondrocyte-sEVs resulted in significant improvements in joint mobility and motor function in OA-affected mice. Proteomic profiling identified serine racemase (SRR) as a key upregulated protein in iChondrocyte-sEVs. Mechanistic studies suggested that SRR may contribute to cartilage regeneration by suppressing the P38/ERK signaling pathway. Conclusions: This study highlights the significant therapeutic potential of iChondrocyte-sEVs, demonstrating their ability to promote both structural and functional regeneration of articular cartilage. These findings suggest a promising novel strategy for OA treatment. The translational potential of this article: This study highlights the therapeutic potential of iChondrocyte-sEVs, demonstrating their ability to promote both structural and functional regeneration of articular cartilage. These findings indicate a clinical conversion potential for OA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.